Results 101 to 110 of about 29,567 (180)

Genomic profile helps to predict the clonal evolution and outcome of BCR-ABL-negative myeloproliferative neoplasms. [PDF]

Transl Oncol
Guo X, Jia W, Yang X, Jia H, Wu H, Wei Y, Can C, He N, Zhang H, Liu W, Yu S, Ma D.   +11 more
europepmc   +1 more source

GPX1 confers resistance to metabolic stress in BCR/ABL-T315I mutant chronic myeloid leukemia cells. [PDF]

Cell Death Discov
Wang JD, Wang JX, Lin ZL, Xu N, Zhang L, Liu JJ, Gao R, Long ZJ.   +7 more
europepmc   +1 more source

Correction to "Molecular Modeling of Single- and Double-Hydrocarbon-Stapled Coiled-Coil Inhibitors against Bcr-Abl: Toward a Treatment Strategy for CML". [PDF]

J Phys Chem B
Carolina P Lima M, Hornsby BD, Lim CS, Cheatham TE.   +3 more
europepmc   +1 more source

Advances in Targeting BCR-ABL^T315I Mutation with Imatinib Derivatives and Hybrid Anti-Leukemic Molecules. [PDF]

Molecules
Tuzikiewicz A, Wawrzyniak W, Kutner A, Żołek T.   +3 more
europepmc   +1 more source

Pharmacological effects of small molecule BCR-ABL tyrosine kinase inhibitors on platelet function. [PDF]

J Pharmacol Exp Ther
Zhang Y, Yang CJ, Melrose AR, Pang J, Schofield K, Song SD, Parra-Izquierdo I, Zheng TJ, Lyssikatos JP, Gross SD, Shatzel JJ, McCarty OJT, Aslan JE.   +12 more
europepmc   +1 more source

[Corrigendum] ND‑09 inhibits chronic myeloid leukemia K562 cell growth by regulating BCR‑ABL signaling. [PDF]

Oncol Rep
Liu YH, Zhu M, Lei PP, Pan XY, Ma WN.
europepmc   +1 more source

BCR-ABL tyrosine kinase [PDF]

Science-Business eXchange, 2009
openaire   +3 more sources

T cell receptors specific for an imatinib-induced mutation in BCR-ABL for adoptive T cell therapy. [PDF]

Front Immunol
Hsu MT, Willimsky G, Hansmann L, Blankenstein T.   +3 more
europepmc   +1 more source

[Allogeneic hematopoietic stem cell transplantation for the treatment of BCR::ABL-negative neutrophilic myeloid neoplasms: a clinical analysis of 12 cases]. [PDF]

Zhonghua Xue Ye Xue Za Zhi
Han TT, He Y, Liu J, Chen Y, Wang FR, Wang JZ, Chen YY, Fu HX, Xu LP, Zhang XH, Huang XJ, Wang Y.   +11 more
europepmc   +1 more source

3D-QSAR Design of New Bcr-Abl Inhibitors Based on Purine Scaffold and Cytotoxicity Studies on CML Cell Lines Sensitive and Resistant to Imatinib. [PDF]

Pharmaceuticals (Basel)
Cabezas D, Delgado T, Sepúlveda G, Krňávková P, Vojáčková V, Kryštof V, Strnad M, Silva NI, Echeverría J, Espinosa-Bustos C, Mellado G, Luo J, Mella J, Salas CO.   +13 more
europepmc   +1 more source